TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed stage IIIB (pleural or pericardial disease) or stage IV non-small cell lung cancer Measurable or evaluable indicator lesion that has not been irradiated Pleural effusions, bone metastases, brain metastases, elevated serum enzymes, and abnormal radionucliotide scans are unacceptable as sole indicator lesions No clinically significant pleural effusions or ascites No grade III or IV edema No prior pneumonectomy No symptomatic or uncontrolled brain or leptomeningeal involvement~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: WBC at least 4,000/mm3 Hemoglobin at least 10 g/dL Platelet count at least 160,000/mm3 Hepatic: Bilirubin no greater than 1.0 mg/dL AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 5 times ULN Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: No unstable cardiac disease requiring treatment Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent active cancer No history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures No active uncontrolled infection No other serious illness or medical condition~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy OR Progression after stable disease or initial response to 1 prior chemotherapy regimen, including 1 preoperative or adjuvant chemotherapy regimen Endocrine therapy: Concurrent steroids allowed if dose is stable Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy Surgery: See Disease Characteristics Other: No prior antifolates At least 7 days since prior folic acid supplements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female renal recipients 18-75 years of age undergoing kidney transplantation, from a primary deceased donor (including expanded criteria donor organs), living unrelated or non-HLA identical living related donor kidney;~* Recipient of a kidney with a cold ischemia time \< 30 hours;~* Graft must be functional (producing greater than or equal to 300 ml of urine within 24 hours after transplantation) at time of randomization.~Exclusion Criteria:~* Donor organ with a cold ischemic time \> 30 hours;~* Patients who produce less than 300 ml of urine in the first 24 hours post-transplantation;~* Patients who are recipients of multiple organ transplants;~* Patients who are recipients of ABO incompatible transplants, or T or B cell cross match positive transplant;~* Patients with current Panel Reactive Antibodies (PRA) level ≥ 50%;~* Patients with severe hypercholesterolemia (350 mg/dl) or hypertriglyceridemia (500 mg/dl). Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable;~* HIV positive patients;~* Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception;~* Decisional impaired subjects who are not medically or mentally capable of providing consent themselves.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate + Low Tacrolimus (Type: ACTIVE_COMPARATOR): Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).
- Everolimus + Very Low Tacrolimus (Type: EXPERIMENTAL): Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interrupting HIV and TB Stigma in the Household in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Index Patient and Household Eligibility:~* Index patient is eligible for contact investigation (TB patient of any age identified in the facility's National TB and Leprosy Programme (NTLP) TB Treatment Register as initiating treatment or returning for 2-week follow-up)~* Index patient or legal guardian agrees to study procedures in addition to routine contact investigation~* Index patient has at least 2 self-reported household contacts age 15 or above~* Household is within the boundaries of the Kampala Capital City Authority, Uganda~* Does not have multi-drug resistant (MDR) TB~Contact Participant Eligibility:~* Household contact age ≥15 years~* Agrees to study procedures in addition to routine contact investigation

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Social Support (Type: EXPERIMENTAL): CHWs will offer HIV testing to the individual nominated by the index patient as most likely to test. If this person is not present, CHWs will decide which contact should be offered testing first. CHWs will use a prosocial script for HIV testing: Knowing your status sets a good example for your household. CHWs will follow an opt-out strategy: This test kit is approved by the Ministry of Health and used in KCCA health facilities. I am going to offer you a free HIV test now, is that okay?. If the initial household contact who is offered HIV testing agrees to test, the CHW will ask if he/she is willing to share his/her decision to test with other members of the household: Would you like to share your decision to test with the others? Sharing is completely optional. However, learning that someone else in their household decided to test sometimes gives people the strength to test themselves. Sharing your decision might help another person find the strength to test.
- Standard of Care (Type: NO_INTERVENTION): As a control for the socio-behavioral intervention, the control arm will lack the socio-behavioral intervention components. The order of testing invitation will be decided by the CHW; and CHWs will be trained at baseline to provide standard, opt-in framing of test offers, without any mention of asking contacts to share their testing decision with other household contacts. Oral HIV kits will also be used in control households.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening.~Exclusion Criteria:~* Symptoms of OAB due to a neurological reason~* Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening~* Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage urinary incontinence~* Use of botulinum toxin therapy of any serotype for any urological condition~* Use of botulinum toxin therapy of any serotype for any non-urological condition in the 12 weeks prior to screening~* History of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB, that may affect bladder function~* Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral Sclerosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
- Placebo/OnabotulinumtoxinA (Type: OTHER): Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients aged ≥18 years~* Signed informed consent form~* Clinically diagnosed acute pharyngitis (TPA ≥5)~* Recent onset of symptoms (≤24 hours)~* Pain intensity of ≥8 on an 11-point NRS~* Difficulty in swallowing (100-mm VAS ≥50 mm)~Exclusion Criteria:~* Patients with strong suspicion of streptococcus A infection (McIsaac score ≥3)~* Positive rapid streptococcus A test (rapid antigen detection test) to exclude the major bacterial pathogen responsible for sore throat~* Purulent tonsillitis~* The use of systemic/local antibiotics in the throat area within 7 days prior to screening and during the study~* The use of any systemic analgesics/local analgesics in the throat area (e.g. non-steroidal drugs, \[acetylsalicylic acid \>100 mg\], paracetamol) within 36 hours prior to screening and during the study~* The use of local anaesthetics for treatment of sore throat within 2 days prior to screening and during the study~* The use of any systemic anti-inflammatory drug/local anti-inflammatory drug in the throat area (e.g. glucocorticoids) within 4 weeks prior to screening and during the study~* The use of any other 'sore throat medication' (e.g., lozenges, drops, sprays) or other 'cold medication' that could have interfered with the results of the study within 7 days prior to screening and during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dorithricin (Type: ACTIVE_COMPARATOR): Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age and not older than 75 who have a specific type of diabetes called Type 2 Diabetes Mellitus~Exclusion Criteria:~* Younger than 18 years of age or older than 75~* Any condition, which in the opinion of the investigator, may not be in the patient's best interest to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Sitagliptin 100 mg
- Sitagliptin 200 mg (Type: EXPERIMENTAL): Sitagliptin 200 mg
- Placebo/Pioglitazone (Type: PLACEBO_COMPARATOR): Placebo/Pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Iron-deficiency anemia (serum ferritin \<30 micrograms, normal hemoglobin electrophoresis, and hemoglobin \<10 mg/dL), planned delivery at Barnes-Jewish Hospital~Exclusion Criteria:~* Non-iron-deficiency anemia, multiple gestation, prenatally diagnosed major fetal anomalies, known aneuploidy, planned delivery at other hospital, inability to obtain consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous iron dextran infusion (Type: EXPERIMENTAL): Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor \& Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
- Oral ferrous sulfate supplementation (Type: ACTIVE_COMPARATOR): Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be 18 years of age and provide written informed consent and sign the HIPAA form~* Must have history of allergic rhinitis~* Must have positive response to Allergen BioCube~Key Exclusion Criteria:~* Must not have a significant illness such as moderate to severe allergic asthmatic reactions~* Must not have compromised lung function~* Must not use any disallowed medications~* Must not have been in an investigational study in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasapaque Nasal Solution (Type: EXPERIMENTAL): 250 ul in each nostril at Day 1 and Day 8
- Placebo Saline Nasal Solution (Type: ACTIVE_COMPARATOR): 250 ul in each nostril at Day 1 and Day 8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years at the time of enrollment~* Clinical diagnosis of external genital warts (located genital, inguinal, perineal or perianal)~* At least 2, but no more than 30 external genital warts~* A total wart area between 12 and 600mm²~* Negative pregnancy test and willingness to use effective contraception (for women of child-bearing potential)~* For partners of male patients who are of child-bearing potential: use of effective contraception during the treatment period~* Written informed consent~* Ability to comply with the requirements of the study~Exclusion Criteria:~* Participation in an investigational trail within 30 days prior to enrollment~* Previous participation in a trial investigating Polyphenon E in the treatment of external genital warts~* Treatment of external genital warts within 30 days prior to enrollment and for the whole study duration~* Systemic intake of virostatics within 30 days prior to enrollment and for the whole study duration~* Systemic intake of immunosuppressive or immunomodulatory medication within 30 days prior to enrollment and for the whole study duration~* Current infection with Herpes genitalis or history of Herpes genitalis infection within the last 3 month~* Any current and/or recurrent pathologically relevant genital infections other than genital warts~* Current known acute or chronic infection with HBV or HCV~* Known HIV infection~* Any current uncontrolled infection~* Organ allograft~* For female patients: pregnancy or lactation~* Known allergies against any of the ingredients of the treatments~* Any chronic or acute skin condition susceptible of interfering with the evaluation of the drug effect~* Any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study~* Internal (vaginal or rectal) warts requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MDD as diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Clinical Trials Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period~* 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score of ≥24 at Screening and Day 1~* Participant in good physical health and has no clinically significant findings, as determined by the investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests~* Participant is willing, able, and eligible to take at least 1 of the 5 ADTs specified in the protocol (an eligible ADT is an ADT that has not been taken during the current depressive episode and for which the participant has no contraindications; further, a participant is not eligible for citalopram if escitalopram has been taken during the current depressive episode, and vice versa)~Exclusion Criteria:~* Has attempted suicide associated with the current episode of MDD~* Participant had onset of the current depressive episode during pregnancy or 4 weeks postpartum, or the participant has presented for screening during the 6-month postpartum period~* Participant has treatment-resistant depression~* History of bipolar disorder, schizophrenia, and/or schizoaffective disorder~* Known allergy to SAGE-217, allopregnanolone, or related compounds~* Has taken antidepressants within 30 days prior to Day 1, and/or has taken fluoxetine within 60 days prior to Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Assigned ADT (Type: ACTIVE_COMPARATOR): Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.
- SAGE-217 + Assigned ADT (Type: EXPERIMENTAL): Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete